Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma

Autor: Fairfax BP, Pratap S, Roberts ISD, Collier J, Kaplan R, Meade AM, Ritchie AW, Eisen T, Macaulay VM, Protheroe A

Publikováno v: BMC Cancer, Vol 12, Iss 1, p 590 (2012)

Abstract Background Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Current evidence-based

Externí odkaz: https://doaj.org/article/7d072e67bb5943888bb27b97591ff7dd

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)

Autor: Adams, R, Wilson, R, Seymour, MT, Meade, AM, Madi, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, TS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::dc800248ce8e59aad2fa6ef0fe27e363
https://ora.ox.ac.uk/objects/uuid:c6e689e0-f21a-45c1-b46e-d733f2e84b8d

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial

Autor: Madi, A, Fisher, D, Wilson, RH, Adams, RA, Meade, AM, Kenny, SL, Nichols, LL, Seymour, MT, Wasan, H, Kaplan, R, Maughan, TS, COIN trial research group

BACKGROUND: COIN compared first-line continuous chemotherapy with the same chemotherapy given intermittently or with cetuximab in advanced colorectal cancer (aCRC). METHODS: Choice between oxaliplatin/capecitabine (OxCap) and oxaliplatin/leucovorin (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::c8a2d5a13f42376a5948af86cc3a3b55

Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.

Autor: Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MK, Quirke P, Seymour MT, Braun, Michael S, Richman, Susan D, Thompson, Lindsay, Daly, Catherine L, Meade, Angela M, Adlard, Julian W, Allan, James M, Parmar, Mahesh K B, Quirke, Philip, Seymour, Matthew T

Publikováno v: Journal of Clinical Oncology; 11/20/2009, Vol. 27 Issue 33, p5519-5528, 10p

Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.

Autor: Raimondi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Nichetti F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany., Stahler A; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany., Wasan HS; Hammersmith Hospital, Imperial College London, London, UK., Aranda E; IMIBIC, Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III, Hospital Universitario Reina Sofía, Córdoba, Spain., Randon G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Kurreck A; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany., Meade AM; MRC Clinical Trials Unit, University College London, Redhill, England, London, UK., Díaz-Rubio E; Department of Medical Oncology, Hospital Clinico San Carlos, Madrid, Spain., Niger M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Stintzing S; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany., Palermo F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Trarbach T; Department of Medical Oncology, Reha-Zentrum am Meer, Bad Zwischenahn, Niedersachsen, Germany., Prisciandaro M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Sommerhäuser G; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany., Fisher D; MRC Clinical Trials Unit, University College London, Redhill, England, London, UK., Morano F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: filippo.pietrantonio@istitutotumori.mi.it., Modest DP; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Sep; Vol. 190, pp. 112945. Date of Electronic Publication: 2023 Jun 19.